- Home
- RNAC
as 11-14-2025 3:38pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 204.6M | IPO Year: | 2016 |
| Target Price: | $40.50 | AVG Volume (30 days): | 154.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.98 - $26.50 | Next Earning Date: | 11-06-2025 |
| Revenue: | $1,091,000 | Revenue Growth: | -97.72% |
| Revenue Growth (this year): | -95.11% | Revenue Growth (next year): | -71.86% |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Simply Wall St.
7 days ago
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership
GlobeNewswire
9 days ago
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
16 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
16 days ago
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
PR Newswire
18 days ago
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Zacks
25 days ago
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
GlobeNewswire
a month ago
Cartesian Therapeutics Announces New Employment Inducement Grant
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.